JED Pharma

nEWS

  • Home
  • About
  • Team
  • Contact

19/7/2022

EC authorisation granted to kidney disease treatment Kinpeygo

0 Comments

Read Now
 
Picture
The treatment was developed by Calliditas and will be marketed by Stada

The European Commission (EC) has granted conditional marketing authorisation for Kinpeygo (budesonide) capsules for the treatment of primary immunoglobulin A nephropathy (IgAN).

The treatment involves adults at risk of rapid disease progression with a specific urine protein-to-creatinine ratio.
READ MORE

Share

0 Comments



Leave a Reply.

Details

    jed pHARMA

    Follow our news stories.

    Categories

    All
    Accenture And NIBRT Announce Collaboration To Speed Up Production Of Life-Saving Medicines
    EC Authorisation Granted To Kidney Disease Treatment Kinpeygo
    Why Irelands Economy Is The Home Of Pharmaceuticals

    RSS Feed

Picture
JED Pharma, Ballingarrane South, Clonmel, Co Tipperary, Ireland. E91V329
(T) +353 (0)52 614 6007  (E) info@jedpharma.com
Company Registration Number ​654267

Privacy Policy
Site By
  • Home
  • About
  • Team
  • Contact